BioMarin Pharmaceutical, Inc. (BMRN)
60.57
+0.14
(+0.23%)
USD |
NASDAQ |
Mar 05, 16:00
61.93
+1.36
(+2.25%)
After-Hours: 20:00
BioMarin Pharmaceutical Cash from Investing (Quarterly) : -42.45M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amicus Therapeutics, Inc. | -6.494M |
| Gilead Sciences, Inc. | -1.835B |
| Merck & Co., Inc. | -11.20B |
| MannKind Corp. | -291.96M |
| AbbVie, Inc. | -1.463B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 99.64M |
| Cash from Financing (Quarterly) | 3.157M |
| Free Cash Flow | 717.02M |
| Free Cash Flow Per Share (Quarterly) | 0.2942 |
| Free Cash Flow to Equity (Quarterly) | 24.87M |
| Free Cash Flow to Firm (Quarterly) | 61.32M |
| Free Cash Flow Yield | 6.09% |